Compare Quest Diagnostics Inc (DGX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tidewater Inc — how do they compare? Quest Diagnostics Inc trades at $230.94 (market cap $25.48B), while Tidewater Inc trades at $85.16 (market cap $4.21B). The key difference: Quest Diagnostics Inc is far larger — about 6.1× Tidewater Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Tidewater Inc for 25 Days on average.
| DGX | TDW | |
|---|---|---|
Market Cap | $25.48B | $4.21B |
Volume | 941,866 | 590,005 |
Sector | Health | Energy |
52-Week High | $247.45 | $100.61 |
52-Week Low | $173.49 | $47.29 |
Typical Hold Time | 56 Days | 25 Days |
Enterprise Value | $31.23B | $4.25B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Tidewater (TDW) trades at $85.16, up 2.11% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with an 18.34% net margin and 19.49% ROE, though recent earnings missed expectations in Q1 and Q2 2026. The company completed the Wilson Sons Ultratug acquisition in August 2026, enhancing its offshore services footprint. Cash flow remains robust with $252.54M net cash flow in 2025.
Outlook is mixed: analyst consensus targets $105.50 (23.9% upside), but earnings volatility and competitive pressures pose risks. Institutional interest is strong, with BlackRock investing $503.20M in Q2 2026. Investors should weigh solid fundamentals against execution risks in a volatile energy market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
